The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
Open accessAbstract
OBJECTIVE—β-Cell function in type 1 diabetes clinical trials is commonly measured by C-peptide response to a secretagogue in either a mixed-meal tolerance test (MMTT) or a glucagon stimulation test (GST). The Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sensitivity, reproducibility, and tolerability of these procedures. RESEARCH DESIGN AND METHODS—In randomized sequences, 148 TrialNet subjects completed 549 tests with up to 2 MMTT and 2 GST tests on separate days, and 118 ECPT subjects completed 348 tests (up to 3 each) with either two MMTTs or two GSTs. RESULTS—Among individuals with up to 4 years’ duration of type 1 diabetes, >85% had measurable stimulated C-peptide values. The MMTT stimulus produced significantly higher concentrations of C-peptide than the GST. Whereas both tests were highly reproducible, the MMTT was significantly more so (R2 = 0.96 for peak C-peptide response). Overall, the majority of subjects preferred the MMTT, and there were few adverse events. Some older subjects preferred the shorter duration of the GST. Nausea was reported in the majority of GST studies, particularly in the young age-group. CONCLUSIONS—The MMTT is preferred for the assessment of β-cell function in therapeutic trials in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationMixed Models: Theory and Applications
Demidenko, E. (2004) · Wiley Series in Probability and Statistics · doi:10.1002/0471728438 · Cited by 488
Correlation Coefficients Measured on the Same Individuals
Dunn, O. J., & Clark, V. (1969) · Journal of the American Statistical Association · doi:10.1080/01621459.1969.10500981 · Cited by 367
The role of measurement reliability in clinical trials
Lachin, J. M. (2004) · Clinical Trials · doi:10.1191/1740774504cn057oa · Cited by 234
Self-citationGreenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 123
Self-citationGuidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes
Greenbaum, C. J., Harrison, L. C., & on behalf of the Immunology of Diabetes Society (2003) · Diabetes · doi:10.2337/diabetes.52.5.1059 · Cited by 86
Self-citationRandom C-peptide in the classification of diabetes
B. Berger, G. S. (2000) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510050216411 · Cited by 86
Mixed Models: Theory and Applications (Wiley Series in Probability and Statistics)
Demidenko, E. (2004) · Wiley-Interscience eBooks · Cited by 76
Cited by
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationA practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
“Two parallel randomized trials by the TrialNet group and by the European C-peptide Trial (ECPT) found moderately superior rises in peak response with the MMTT [19].”
BackgroundMethodInfluentialThe clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Self-citationGAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520
Self-citationKeenan, H. A., Sun, J. K., Levine, J., Doria, A., Aiello, L. P., Eisenbarth, G., Bonner-Weir, S., & King, G. L. (2010) · Diabetes · doi:10.2337/db10-0676 · Cited by 500
Implementing a reference measurement system for C-peptide: successes and lessons learned
Little, R. R., Wielgosz, R. I., Josephs, R., Kinumi, T., Takatsu, A., Li, H., Stein, D., & Burns, C. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269274 · Cited by 383
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationMoran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Self-citationGAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Self-citationFall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Self-citationLong, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Self-citationOram, R. A., Jones, A. G., Besser, R. E. J., Knight, B. A., Shields, B. M., Brown, R. J., Hattersley, A. T., & McDonald, T. J. (2014) · Diabetologia · doi:10.1007/s00125-013-3067-x · Cited by 298
Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes
Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1952 · Cited by 261
Self-citationVerapamil and beta cell function in adults with recent-onset type 1 diabetes
Ovalle, F., Grimes, T., Xu, G., Patel, A. J., Grayson, T. B., Thielen, L. A., Li, P., & Shalev, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0089-4 · Cited by 249
Herold, K. C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P., Sayre, P., Bianchine, P., Wong, E., Seyfert-Margolis, V., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.04.007 · Cited by 219
“However these studies were cross-sectional and did not evaluate changes in insulin production over time [21,22].”
Self-citationKielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
“Therefore, although more timeconsuming, the MMTT may better mimic the actual pancreatic response to ingestion of a meal during everyday life and has been shown to be more reproducible and better tolerated than the GST.(21)”
BackgroundSelf-citationΒ cell dysfunction exists more than 5 years before type 1 diabetes diagnosis
Evans-Molina, C., Sims, E. K., DiMeglio, L. A., Ismail, H. M., Steck, A. K., Palmer, J. P., Krischer, J. P., Geyer, S., Xu, P., Sosenko, J. M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120877 · Cited by 116
“Longitudinal monitoring of aAb+ individuals consisted of semiannual or annual study visits that included a standard protocol 2-hour OGTT (28).”
InfluentialLessons From the Mixed-Meal Tolerance Test
Besser, R. E. J., Shields, B. M., Casas, R., Hattersley, A. T., & Ludvigsson, J. (2013) · Diabetes Care · doi:10.2337/dc12-0836 · Cited by 91
Self-citationIdentification of Autoantibody-Negative Autoimmune Type 2 Diabetic Patients
Brooks-Worrell, B. M., Reichow, J. L., Goel, A., Ismail, H., & Palmer, J. P. (2011) · Diabetes Care · doi:10.2337/dc10-0579 · Cited by 83
Besser, R. E. J., Ludvigsson, J., Jones, A. G., McDonald, T. J., Shields, B. M., Knight, B. A., & Hattersley, A. T. (2011) · Diabetes Care · doi:10.2337/dc10-2114 · Cited by 82
Self-citationBogun, M. M., Bundy, B. N., Goland, R. S., & Greenbaum, C. J. (2020) · Diabetes Care · doi:10.2337/dc19-2288 · Cited by 72
Self-citationHope, S. V., Knight, B. A., Shields, B. M., Hattersley, A. T., McDonald, T. J., & Jones, A. G. (2016) · Diabetic Medicine · doi:10.1111/dme.13142 · Cited by 68
Ludvigsson, J., Sumnik, Z., Pelikanova, T., Nattero Chavez, L., Lundberg, E., Rica, I., Martínez-Brocca, M. A., Ruiz de Adana, M., Wahlberg, J., Katsarou, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0318 · Cited by 58
Self-citationPleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial
Krogvold, L., Mynarek, I. M., Ponzi, E., Mørk, F. B., Hessel, T. W., Roald, T., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02576-1 · Cited by 55
Self-citationPozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
Self-citationLudvigsson, J., Chéramy, M., Axelsson, S., Pihl, M., Åkerman, L., Casas, R., & for the clinical GAD‐study group in Sweden (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2503 · Cited by 42
Self-citationLatres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35
Self-citationThe Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults
Ferrara, C. T., Geyer, S. M., Evans-Molina, C., Libman, I. M., Becker, D. J., Wentworth, J. M., Moran, A., Gitelman, S. E., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01490 · Cited by 33
Soare, A., Khazrai, Y. M., Fontana, L., Del Toro, R., Lazzaro, M. C., Di Rosa, C., Buldo, A., Fioriti, E., Maddaloni, E., Angeletti, S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.023 · Cited by 15
Self-citationMynarek, I. M., Krogvold, L., Mørk, F. B., Lawaetz, T. W. H., Roald, T., Fagerland, M. W., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2121 · Cited by 4
Self-citation
Metadata
- Authors
- Greenbaum, C. J., Mandrup-Poulsen, T., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., Kolb, H., & The Type 1 Diabetes Trial Net Research Group and the European C-Peptide Trial Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-10-01
- Volume
- 31
- Issue
- 10
- Pages
- 1966-1971
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2118174270
- Cited by
- 285
- References
- 12
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.